BiotechTube

MACI

Phase 3Recruiting
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chondral Defect

Conditions

Chondral Defect, Osteochondritis Dissecans (OCD), Articular Cartilage Defect, Articular Cartilage Disorder of Knee

Trial Timeline

Oct 24, 2018 → Jun 1, 2027

NCT ID
NCT03588975

About MACI

MACI is a phase 3 stage product being developed by Vericel for Chondral Defect. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03588975. Target conditions include Chondral Defect, Osteochondritis Dissecans (OCD), Articular Cartilage Defect.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03588975Phase 3Recruiting

Competing Products

1 competing product in Chondral Defect

See all competitors
ProductCompanyStageHype Score
autologous cultured chondrocytes on porcine collagen membraneVericelPhase 3
72

Other Products from Vericel

Carticel (autologous cultured chondrocyte) implantationApproved
80
Ixmyelocel-TPhase 3
72
autologous cultured chondrocytes on porcine collagen membranePhase 3
72
Ixmyelocel-TPhase 3
72
autologous cultured chondrocytes on porcine collagen membranePhase 3
72